Navidea Biopharmaceuticals, Inc.
NAVBDelisted Jan 16, 2024- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000810509
Navidea Biopharmaceuticals, Inc. was delisted on Jan 16, 2024; its insiders filed their last Form 4 on Dec 5, 2023; 24 institutions reported holding it in 13F filings for Q3 2023, worth $225.8K in total; no superinvestor held it.
13F holders, Q4 2023
Institutional positions in Navidea Biopharmaceuticals, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
NAVB is no longer listed, and 13F filings after Q3 2023 list far fewer holders. See Q3 2023
- Institutional holders
- 4
- −19 vs. Q3 2023
- Shares held
- 11.2K
- −2.49M (−99.6%) vs. Q3 2023
- Total value
- $469
- −$224.4K (−99.8%) vs. Q3 2023
- New holders
- 2
- 0 more added
- Sold out
- 21
- 0 more reduced
1 institution that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NAVB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 2 | $0 |
| Q3 2025 | 1 | $0 |
| Q2 2025 | 1 | $0 |
| Q1 2025 | 2 | $0 |
| Q4 2024 | 1 | $0 |
| Q3 2024 | 2 | $0 |
| Q2 2024 | 2 | $0 |
| Q1 2024 | 2 | $13 |
| Q4 2023 | 4 | $469 |
| Q3 2023 | 24 | $225.8K |
| Q2 2023 | 23 | $138.5K |
| Q1 2023 | 30 | $364.4K |
| Q4 2022 | 28 | $339.3K |
| Q3 2022 | 25 | $379.6K |
| Q2 2022 | 26 | $1.08M |
| Q1 2022 | 25 | $1.19M |
| Q4 2021 | 31 | $1.68M |
| Q3 2021 | 29 | $2.76M |
| Q2 2021 | 31 | $3.08M |
| Q1 2021 | 35 | $3.77M |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Navidea Biopharmaceuticals, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Baader Bank INC | 10,630 | $435 | 0.00% | +10,630 | New |
| Parallel Advisors, LLC | 350 | $19 | 0.00% | 00.0% | Unchanged |
| Advisory Services Network, LLC | 250 | $14 | 0.00% | +250 | New |
| Beacon Capital Management, LLC | 10 | $1 | 0.00% | 00.0% | Unchanged |
| Allred Capital Management, LLC | 0 | $0 | 0.00% | −466,688−100.0% | Sold out |
| State Street Corp | 0 | $0 | 0.00% | −412,743−100.0% | Sold out |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −368,830−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −333,069−100.0% | Sold out |
| Vanguard Group Inc | 0 | $0 | 0.00% | −276,491−100.0% | Sold out |
| Warberg Asset Management LLC | 0 | $0 | 0.00% | −194,997−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −149,612−100.0% | Sold out |
| BlackRock Inc. | 0 | $0 | 0.00% | −113,030−100.0% | Sold out |
| Level Four Advisory Services, LLC | 0 | $0 | 0.00% | −55,555−100.0% | Sold out |
| Boothbay Fund Management, LLC | 0 | $0 | 0.00% | −40,000−100.0% | Sold out |
| Northern Trust Corp | 0 | $0 | 0.00% | −39,414−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −31,553−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −8,937−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −5,632−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −4,416−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −1,604−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −1,300−100.0% | Sold out |
| Sound Income Strategies, LLC | 0 | $0 | 0.00% | −599−100.0% | Sold out |
| GWM Advisors LLC | 0 | $0 | 0.00% | −412−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −300−100.0% | Sold out |
| Kelly Financial Services LLC | 0 | $0 | 0.00% | −50−100.0% | Sold out |
| Pathstone Family Office, LLC | – | – | – | – | Not filed |